- Home
- VLO vs TAK Comparison
VLO vs TAK Comparison
Compare VLO & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VLO | TAK |
|---|---|---|
| Founded | 1980 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.9B | 43.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VLO | TAK |
|---|---|---|
| Price | $167.11 | $14.51 |
| Analyst Decision | Buy | |
| Analyst Count | 18 | 0 |
| Target Price | ★ $180.18 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 2.6M |
| Earning Date | 01-29-2026 | 01-29-2026 |
| Dividend Yield | 2.69% | ★ 3.68% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.78 | 0.14 |
| Revenue | ★ $116,553,000,000.00 | $29,846,840,032.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.59 |
| P/E Ratio | ★ $35.25 | $102.85 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $99.00 | $12.80 |
| 52 Week High | $185.62 | $15.69 |
Technical Indicators
Market Signals| Indicator | VLO | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 59.90 |
| Support Level | $170.73 | $14.20 |
| Resistance Level | $177.99 | $14.53 |
| Average True Range (ATR) | 4.47 | 0.13 |
| MACD | -1.38 | 0.01 |
| Stochastic Oscillator | 7.35 | 87.80 |
Price Performance
Historical ComparisonAbout VLO Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 15 refineries, with a total throughput capacity of 3.2 million barrels a day in the US, Canada, and the United Kingdom. Valero also owns 12 ethanol plants with capacity of 1.6 billion gallons a year and holds a 50% stake in Diamond Green Diesel, which can produce 1.2 billion gallons per year of renewable diesel.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.